← Back to TCM Global · All articles

China's Ginseng Cosmetics Market: An Investor's Read

ginseng cosmetics investor read

2026-10-23

The Contradiction Worth Studying

Giant Biogene is investing a decade of R&D and new capital into rare ginsenosides — while its stock touched 22.08 HKD in October, giving back nearly three years of gains. 2026 H1: revenue down 6.3%, net profit down 20.5%. Citi noted Q3 online beauty sales growth slowing, with the company's GMV recovering from a low base but 'not yet encouraging.'

A promising ingredient story inside a struggling stock. Both can be true. Here's the framework for reading it.

The Bull Case

  1. Real technology assets: five rare saponins at hundred-kilogram scale, CK cosmetic registration, ten years of data
  2. Strategic clarity: the second-engine strategy explicitly replicates the collagen playbook that built the company
  3. Category timing: Chinese beauty consumers are rewarding science-backed heritage actives
  4. Multi-category optionality: sleep, anemia, fatigue and memory research opens doors beyond beauty

    5. The Bear Case

    1. Core business pressure: 80%+ of revenue from two collagen brands facing growth slowdown
    2. No revenue visibility: ginsenoside-specific sales aren't disclosed; health-food segments under 0.3% of revenue
    3. Execution history: the Xin'an brand closure shows consumer-brand execution is not yet proven
    4. Market conditions: category growth slowing sector-wide

      5. The Metrics That Will Decide It

      1. 1'me Yiwuo repurchase rate (watch 2027 quarters, not launch weeks)
      2. Revenue disclosure granularity — when ginsenoside products merit their own line item, that's a signal
      3. Additional ingredient registrations (Rk3, Rh1, Rg5 cosmetic paths)
      4. Collagen stabilization — the second engine only matters if the first keeps running

        5. The Broader Lesson

        For the beauty-health industry, this is the test case for ingredient-platform companies: can a biotech with a proven first actives category build a second on a different chemistry? The answer will shape how capital treats every 'second ingredient' story in Chinese beauty tech.

        The Takeaway

        Stocks price the present; ingredient platforms build the future. The ginsenoside push is a multi-year option — valuable if management keeps funding it through the slow middle, worthless if impatience cuts it at year five.

        Explore more Eastern wellness wisdom at TCM Global.